Gary Rabin | Chief Executive Officer
Advanced Cell Technology

Gary Rabin, Chief Executive Officer, Advanced Cell Technology

Gary Rabin has a 23-year career in finance and operations that primarily encompasses investing in, managing and capital-raising for small-cap and emerging growth companies. From 2007 to 2010, he was the Managing Partner of GR Advisors, LLC, investment manager for two long/short hedge funds focused on the media and communications industry. Until June 2007, he was a Portfolio Manager at MACInvestment Management, LLC (“MAC”), which he joined in November 2005. MAC was a long/short fundamental equity hedge fund concentrating on growth-oriented stocks including technology, communications and healthcare. Previously, he was a Managing Director and Portfolio Manager at Marketus Associates, a long/short hedge fund where he focused on communications, healthcare services, energy and special situations. Prior to that, he was Managing Director and Co-Head of the Media and Telecom Investment Banking Group at CIBC World Markets (“CIBC”), where he was responsible for all corporate finance and M&A, financial restructurings, and principal investing activities (both debt and equity) within the sector. Before joining CIBC, Mr. Rabin served in an operating capacity at a broadband services company when he was Chief Strategy Officer of CAIS Internet, Inc. (“CAIS”). At CAIS, he was responsible for raising over $500 million of financing commitments in both the public equity markets and from his relationships at Kohlberg, Kravis Roberts & Co., Qwest Communications, Cisco, Nortel, 3Com and Microsoft. Mr. Rabin has also started and served as Managing Director and Head of the Global Telecom Investment Banking Group at ING Barings Furman Selz, and was a founder of the telecom group at UBS Securities. He began his career in finance in 1987, and concentrated on energy, utilities, and metals until 1993. Throughout his career, Mr. Rabin has been responsible for building and developing businesses. Mr. Rabin earned an AB in Economics from the University of Michigan.

Share this

Appearances at this years' conference:

DAY ONE - Stream A: Cell Therapy & Regenerative Medicine


@ 16.45
Successes and ongoing advancements of human clinical trial for the treatment of SMD & Stargardt’s disease

  • › Gary Rabin, Chief Executive Officer, Advanced Cell Technology
Sponsors
Gold Sponsor
Sigma-Aldrich at World Stem Cells & Regenerative Medicine Congress 2012
Gold Sponsor
Lonza at World Stem Cells & Regenerative Medicine Congress 2012
Gold Sponsor
ATMI N.V. at World Stem Cells & Regenerative Medicine Congress 2012
Gold Sponsor
Invetech at World Stem Cells & Regenerative Medicine Congress 2012
Silver Sponsor
EMD Millipore at World Stem Cells & Regenerative Medicine Congress 2012
Associate sponsor
Pathfinder Cell Therapy Inc at World Stem Cells & Regenerative Medicine Congress 2012
Associate Sponsor
Cellgenix at World Stem Cells & Regenerative Medicine Congress 2012
Associate Sponsor
Medipost Co., Ltd. at World Stem Cells & Regenerative Medicine Congress 2012
Associate Sponsor
Double Helix at World Stem Cells & Regenerative Medicine Congress 2012
Associate Sponsor
Cardio3 BioSciences S.A at World Stem Cells & Regenerative Medicine Congress 2012
Associate Sponsor
Cellular Dynamics International at World Stem Cells & Regenerative Medicine Congress 2012
Exhibitor
Sarstedt AG & Co at World Stem Cells & Regenerative Medicine Congress 2012
Exhibitor
World Courier at World Stem Cells & Regenerative Medicine Congress 2012
Exhibitor
Quality Assistance S.A. at World Stem Cells & Regenerative Medicine Congress 2012
Exhibitor
Caridian BCT at World Stem Cells & Regenerative Medicine Congress 2012
Exhibitor
Humanzyme at World Stem Cells & Regenerative Medicine Congress 2012
Exhibitor
Miltenyi Biotec at World Stem Cells & Regenerative Medicine Congress 2012